No abstract

Although well researched and praised in academic publications, function modelling (FM) does not have gained much traction in industrial application. To investigate into possible reasons for this, this publication researches literature of nine different projects where enhanced function-means modelling has been applied. The projects are analysed for their purpose of FM-use, applied benefits and discovered challenges of the FM approach. From this, the main challenges for FM application are the abstraction level of the modelling language as well as the lack of an interface to CAD modelling.

The quality of a coated pharmaceutical tablet can be strongly affected by the interactions of water droplets with the porous substrate during processes such as coating process. Three different mechanisms co-exist in the coating process: water spreading, absorption and evaporation. Disentangling the fundamental understanding of these phenomena can therefore be crucial for achieving a higher quality of the products (e.g. a longer shelf-life of the tablets) and for controlling the efficiency of the process. This paper aims to investigate the spreading and absorption mechanisms after droplet impingement on a tablet using a Lattice-Boltzmann methodology. Our numerical results (droplet height and spreading, penetration depth and absorbed volume) are in a good agreement with experimental data and numerical simulations available in the literature. In particular, the spreading phase is characterised by the capillary spreading time scale, as confirmed by previous studies. In contrast to previous studies, we find that the absorption process begins at times shorter than the capillary spreading time but with a different power-law in the absorbed volume. We explain this behaviour through a modified Washburn law that takes into account three-dimensional effects. Our data can be used as a benchmark to test novel mathematical models.

Emerging research within the field of personalised medicines has aimed to enhance patient treatment through the use of pharmaceutical products that are customised to the individual needs and preferences of the patient. The currently dominant production platforms of pharmaceutical products, however, regard a mass production paradigm and are thus unfeasible for the production and provision of personalised medicines. The production platforms are not designed or are intended for a customisation context. Operating such a context with the current supply chain entails challenges such as increasing costs, time to patient and efforts in quality assurance activities. To address these challenges, this paper presents four reconfigured pharmaceutical supply chain designs. A qualitative operational performance assessment elicits the strengths and weaknesses of the respective supply chain design operating in a customisation context. The results suggest that a later point of variegation, that is, the point in the supply chain where the final customisation is achieved, can relieve the operational effort of the stakeholders in the supply chain while providing the benefits of personalised medicines, that is, an enhanced treatment outcome of the patient. A trade-off remains, however, between the supply chain’s decreased operational effort and degree of necessary reconfigurations, such as introducing new functions to stakeholder operation, reallocating activities to other stakeholders or educating stakeholders.

Despite advances in pharmacological research providing means for individually customized patient attribute treatments, the 'one-size-fits-all' paradigm remains. Customization is associated with cost increases and the value assessment of customized medicinal products shows upon a narrow economic focus. Inspired by value models, emerging in manufacturing industry research, this study suggests a novel methodology encompassing a full sustainability perspective, including the social, economic and ecological dimension, for design decision support for medicinal products. A concept screening matrix is adapted, using sustainability criteria as value indicators. The focus is to create value for the whole pharmaceutical value chain whilst keeping the core purpose of medicinal products, i.e. to bring societal benefits. An illustrative case study presents an application of the methodology on a commercial product for curing hypertension. The traditional product design for hypertension treatment is compared to a customized product design. Results indicate that a customized product design is preferable if value is to be created from a social or/and an ecological sustainability perspective.